Neurophth Therapeutics
Wuhan
About Neurophth Therapeutics
Neurophth is China's first gene therapy company for ophthalmic diseases. As a clinical-stage company, Neurophth is dedicated to discovering and developing gene therapies for patients suffering from blindness and other eye diseases globally.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 101 – 250
- Estimated revenue: $100K – $500K
- Total funding: $237.4M
- Funding stage: Late Stage Venture
- Last round: Series C (Aug 2023)
- Website: neurophth.com
- Phone: +027-65524119
Industries & Categories
Biotechnology, Life Science
Social Profiles
Canonical: https://fsome.com/organization/neurophth-therapeutics-88732 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.